|Videos|March 25, 2021

Immunotherapy revolutionizes frontline treatment in advanced RCC

Michael E. Hurwitz, MD, PhD, discusses how immune checkpoint inhibitors have transformed the first-line setting in advanced renal cell carcinoma.

Michael E. Hurwitz, MD, PhD, an associate professor of Internal Medicine at the Yale Cancer Center, discusses how immune checkpoint inhibitor–based combination have dramatically altered the frontline treatment paradigm for patients with advanced renal cell carcinoma.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


Latest CME